ARCHIVES

DCT Board Okays Extension Of Phase 1 Master Agreements, Increase To $4 Million

This article is from The Cancer Letter archive.

Vol. 13 No. 09 | February 27, 1987

Download PDF Visit The Full Archive

Related Articles

NCI Offers 200 Cell Lines to Scientist

May 6, 1983

NCCS Networker Volume 5 Issue 4, Fall 1991

September 13, 1991

Chart of FY 1991 Budget For NCI By Mechanism

February 2, 1990

Impact Of DRGs On Clinical Research Less Than First Feared, Speakers Tell NIH Directors Meeting

June 20, 1986

GAO Report: Taxol CRADA “Successful,” But Not Great Financial Deal.

June 27, 2003

New Drug Approvals Point To Greater Role Of Randomization In Cancer Clinical Trials. European Standards Will Demand More Rigor.

February 24, 2006